Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 509 |
| Synonyms | |
| Therapy Description |
AMG 509 is a bispecific T-cell engager targeting STEAP1 and CD3, potentially resulting in increased immune response against STEAP1-expressing tumors cells (PMID: 37861452). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 509 | AMG509|AMG-509|Xaluritamig | CD3 Antibody 119 | AMG 509 is a bispecific T-cell engager targeting STEAP1 and CD3, potentially resulting in increased immune response against STEAP1-expressing tumors cells (PMID: 37861452). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06613100 | Phase I | AMG 509 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Recruiting | USA | DEU | 0 |
| NCT06555796 | Phase I | AMG 509 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | Recruiting | USA | AUS | 0 |
| NCT06691984 | Phase III | AMG 509 Enzalutamide Abiraterone Cabazitaxel | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | TUR | SWE | POL | NLD | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
| NCT04221542 | Phase I | AMG 509 Abiraterone + AMG 509 AMG 509 + Enzalutamide | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ESP | DEU | CHE | AUS | 5 |
CKB BOOST